The effect of BCG vaccination in treatment of patients with type 1 diabetes mellitus

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017042919940N2

Enrollment

Registered

2017-05-29

Start date

2017-06-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endocrine disease. E10-E14

Interventions

Treatment - Drugs

Placebo

In interventional group, the patients will take BCG vaccination 0.2 cc intradermal in deltoid muscle in baseline, 4 weeks later, 1 year after the first dose.

In control group, the patients will take normal saline 0.2 cc intradermal in deltoid muscle in baseline, 4 weeks later, 1 year after the first dose.

Intervention 1: In interventional group, the patients will take BCG vaccination 0.2 cc intradermal in deltoid muscle in baseline, 4 weeks later, 1 year after the first dose. Intervention 2: In control

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: patients with type 1 diabetes mellitus Duration of insulin injection at least for 10 years Age 18 to 55 years negative HIV antibody Hb A1C 8% Using high dose of aspirin( > 160 mg per day) Having HIV infection

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting blood sugar. Timepoint: 0-1-3-4-8-12-16-20-24-28-32-36-40-44-48-52 weeks after intervention. Method of measurement: Glucometer.	—

Secondary

Measure	Time frame
HbA1C. Timepoint: 0-4 -8- 12- 20- 32- 44-52 weeks after starting the study. Method of measurement: Enzymatic method.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehzad Shakerian

Isfahan University of Medical Sciences

behzad5tyahoo.com@00

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 14, 2026